Compare CACI & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CACI | MDGL |
|---|---|---|
| Founded | 1962 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 12.5B |
| IPO Year | 1979 | N/A |
| Metric | CACI | MDGL |
|---|---|---|
| Price | $581.76 | $556.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | ★ $616.50 | $580.77 |
| AVG Volume (30 Days) | 272.4K | ★ 300.6K |
| Earning Date | 01-21-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.06 | N/A |
| EPS | ★ 22.62 | N/A |
| Revenue | ★ $8,858,558,000.00 | $740,640,000.00 |
| Revenue This Year | $10.72 | $435.63 |
| Revenue Next Year | $6.19 | $52.56 |
| P/E Ratio | $25.82 | ★ N/A |
| Revenue Growth | 12.61 | ★ 864.21 |
| 52 Week Low | $318.60 | $265.00 |
| 52 Week High | $632.77 | $615.00 |
| Indicator | CACI | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 58.71 | 45.07 |
| Support Level | $553.49 | $532.45 |
| Resistance Level | $572.23 | $589.98 |
| Average True Range (ATR) | 14.86 | 21.40 |
| MACD | 3.59 | -5.96 |
| Stochastic Oscillator | 61.28 | 28.24 |
CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.